Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812

Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812

Abstract INTRODUCTION CT1812 (zervimesine) is an orally dosed modulator of the sigma‐2 receptor (S2R) currently in clinical development for the treatment of Alzheimer's disease (AD). CT1812 has been shown in preclinical and early clinical trials to selectively prevent and displace binding of am...

Full description

Saved in:
Bibliographic Details
Main Authors: Valentina Di Caro, Eunah Cho, Hilary A. North, Jill Caldwell, Kiran Pandey, Duc Duong, Michael Grundman, Willem deHaan, Everard G. Vijverberg, Charlotte E. Teunissen, Anthony O. Caggiano, Nicholas T. Seyfried, Mary E. Hamby
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Aβ oligomers
Alzheimer's disease
CSF biomarkers
CSF pharmacodynamic biomarkers
CT1812 (zervimesine)
functional connectivity (alpha AEC‐c)
Online Access:https://doi.org/10.1002/trc2.70119
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/trc2.70119

Similar Items